|
Chelsea Therapeutics Granted MHRA Approval to Begin Phase II Trial of Droxidopa in Fibromyalgia…
FOXBusiness - Fibromyalgia is a chronic and debilitating condition that is characterized by widespread pain and stiffness throughout the body, accompanied by severe … |